Skip to content
OpenCapital
Get started

The Beauty Health Company SKIN Amortization expense related to capitalized debt issuance costs

Amortization expense related to capitalized debt issuance costs at other companies

Helen Of Troy logo
Helen Of TroyHELE
——

Other financials

Income statement

See full
Revenue$64.9M-6.7%
Gross profit$44.4M-8.5%
Operating income-$1.8M+85.0%
Net income-$6.6M+34.3%
EPS (diluted)-$0.05+37.5%

Balance sheet

See full
Cash & equivalents$204.4M-45.2%
Total debt$125.9M+756%
Total equity$55.2M+19.9%
Total assets$473.2M-29.8%

Cash flow

See full
Operating cash flow-$5.6M-285%
CapEx$224.0K+398%
Free cash flow-$5.8M-296%

Valuation

See full
Market cap$89.75M-61.5%
Enterprise value$11.24M-96.2%
P/S0.3×-0.4×

Profitability

See full
Gross margin64.9%+8.3pp
Operating margin-3.6%-1.6pp
Net margin-2%-0.9pp
FCF margin9.6%—

Returns & leverage

See full
Return on equity-12%-5.4pp
Debt / equity2.3×+2.0×
Current ratio1.8×-5.7×

Where this comes from

Reported directly by The Beauty Health Company in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.

The official record: The Beauty Health Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Beauty Health Company's amortization expense related to capitalized debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is The Beauty Health Company's amortization expense related to capitalized debt issuance costs?
The Beauty Health Company (SKIN) reported amortization expense related to capitalized debt issuance costs of $1.01M in Q1 2026.
How has The Beauty Health Company's amortization expense related to capitalized debt issuance costs changed year-over-year?
The Beauty Health Company's amortization expense related to capitalized debt issuance costs increased by 28.5% year-over-year, from $786K to $1.01M.
What is the long-term trend for The Beauty Health Company's amortization expense related to capitalized debt issuance costs?
Over 3 years (2022 to 2025), The Beauty Health Company's amortization expense related to capitalized debt issuance costs has grown at a -4.9% compound annual growth rate (CAGR), from $4.23M to $3.64M.